GENENTECH, INC for GENENTECH INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 21, 2020 | $1,520,000 | Replaced |
| 4th Quarter - Amendment (this page) | Sep 29, 2021 | $1,580,000 | Yes |
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Foreign Relations FOR
Issues related to Foreign Agents Registration Act (FARA including Disclosing Foreign Influence Act -H.R. 4170/S. 2039
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE LYTTON PHILLIPS | — |
| ANDREW WESLEY WOMACK | — |
Copyright/Patent/Trademark CPT
S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| ANDREW WESLEY WOMACK | — |
Medical/Disease Research/Clinical Labs MED
- Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT New | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| ANDREW WESLEY WOMACK | — |
Trade (domestic/foreign) TRD
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| ANDREW WESLEY WOMACK | — |
Medicare/Medicaid MMM
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S.2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S.3013, Encourging Innovative Benefti Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT New | — |
| ELISE MARIE CONNER | — |
| BRIAN MALONEY New | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Taxation/Internal Revenue Code TAX
- Issues related to the tax reform bill and implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
Financial Institutions/Investments/Securities FIN
- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE LYTTON PHILLIPS | — |
Health Issues HCR
H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT New | — |
| ELISE MARIE CONNER | — |
| BRIAN MALONEY New | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Budget/Appropriations BUD
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| BRIAN MALONEY | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Pharmacy PHA
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 Issues - Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Issues related to prescription drug value
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT New | — |
| ELISE MARIE CONNER | — |
| BRIAN MALONEY New | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.